J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
First published on March 19, 2009, doi:10.1177/0091270009333017

The Journal of Clinical Pharmacology 2009;49:582.

This Article
Right arrow Full Text (JCP OnlineFirst[PDF])
Right arrow All Versions of this Article:
0091270009333017v1
49/5/582    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pérez, C.
Right arrow Articles by Rejas, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pérez, C.
Right arrow Articles by Rejas, J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
©© 2009 American College of Clinical Pharmacology, Inc.
The Journal of Clinical Pharmacology, 10.1177/0091270009333017

Article

Trigeminal Neuralgia Treated With Pregabalin in Family Medicine Settings: Its Effect on Pain Alleviation and Cost Reduction

Concepción Pérez 1, María T. Saldaña 2, Ana Navarro 3, Silvia Martínez 4, and Javier Rejas 5*

1 University Hospital La Princesa
2 Primary Care Health Centre Raíces
3 Primary Care Health Centre Puerta del Angel
4 European Biometrics Institute
5 Pfizer España

* To whom correspondence should be addressed. E-mail: marina.desalas{at}pfizer.com.


  Abstract
The purpose of this study is to analyze the effect of pregabalin (PGB) on pain alleviation, use of health care and non–health care resources, and associated costs in patients with trigeminal neuralgia under usual clinical practice in primary care settings. Sixty-five PGB-naïve patients receiving PGB as monotherapy (n = 36, 55%) or combined with other drugs (n = 29, 45%) fulfill criteria for inclusion in a secondary analysis from a 12-week, multicenter, observational prospective study aimed to ascertain the cost of illness in subjects with neuropathic pain. Pain is evaluated using the Short Form McGill Pain Questionnaire. Use of health care and non–health care resources and lost workdays equivalents (LWDEs) are also recorded. PGB significantly reduces pain scores, use of health care resources (ancillary tests and unscheduled medical visits), and number of LWDEs. Additional cost of PGB treatment (+{euro}174 ± 106) is broadly compensated for by a reduction in both health care costs (–{euro}621 ± 1211, P < .001) and indirect costs (–{euro}1210 ± 1141, P < .001). It is concluded that PGB as monotherapy or combined with other drugs is effective in pain management in patients with trigeminal neuralgia and reduces the cost of illness.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2009 by the American College of Clinical Pharmacology